PCSK9 and hyperlipidemia: In response to this challenge, an inhibitor targeting proprotein convertase subtilisin-kexin type 9 (PCSK9) has been developed as a therapeutic intervention for hyperlipidemia, effectively achieving a significant reduction in low-density lipoprotein cholesterol (LDL-C) levels within a month.